Correction: Xiang, S., et al. Schisandrin B Induces Apoptosis and Cell Cycle Arrest of Gallbladder Cancer Cells. Molecules 2014, 19, 13235–13250

Xiang, Sheng; Wang, Xuan; Li, Huai-Feng; Shu, Yijun; Bao, Runfa; Zhang, Fei; Yang, Cao; Ye, Yuanyuan; Weng, Hao; Wu, Wenzhi; Mu, Jian; Wu, Xiangsong; Li, Maolan; Hu, Yunping; Jiang, Lin; Tan, Zhen; Lü, Wei; Liu, Feng; Liu, Yingbin

doi:10.3390/molecules21050673

Cited by 2 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different from previous studies (Song et al, 2011;Wang et al, 2011Wang et al, , 2012Zhang et al, 2013;Li et al, 2015Li et al, , 2016Ma et al, 2015;Xu et al, 2015;Ye et al, 2015;Han et al, 2016;Jiang et al, 2016), assessing the effects of microRNA-138 on tumor cells, our studying showed that miR-138-5p not only inhibits the proliferation of tumor cells but also regulates the tumor immune micro-environment. Lent-miR-138-5p treatment increased the number of tumor-infiltrated DCs and regulated the maturation of DCs in the A549/3LL-bearing mice model, and promoted DCs' capability to inhibit tumor cells and enhance T cells to kill tumor cells.…”

Section: Discussioncontrasting

confidence: 94%

MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment

Song

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is still challenging for treatment owing to immune tolerance and evasion. MicroRNA-138 (miR-138) not only acts as a tumor suppressor to inhibit tumor cell proliferation and migration but also regulates immune response. The regulatory mechanism of miR-138 in NSCLC remains not very clear. Herein, we demonstrated that miR-138-5p treatment decreased the growth of tumor cells and increased the number of tumor-infiltrated DCs. miR-138-5p not only down-regulated the expression of cyclin D3 (CCND3), CCD20, Ki67, and MCM in A549/3LL cells, but also regulated the maturation of DCs in A549-bearing nude mice and the 3LL-bearing C57BL/6 mouse model, and DCs’ capability to enhance T cells to kill tumor cells. Furthermore, miR-138-5p was found to target PD-L1 to down-regulate PD-L1 on tumor cells to reduce the expression of Ki67 and MCM in tumor cells and decrease the tolerance effect on DCs. miR-138-5p also directly down-regulates the expression of PD-L1 and PD-1 on DCs and T cells. Similar results were obtained from isolated human non-small cell lung cancer (NSCLC) cells and DCs. Thus, miR-138-5p inhibits tumor growth and activates the immune system by down-regulating PD-1/PD-L1 and it is a promising therapeutic target for NSCLC.

show abstract